Category: Tetrahydropyrans

85064-61-5, Tetrahydropyranyl-4-acetic acid is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a suspension of 0.55 g of LiAlH4 (13.9 mmol) in THF (10 mL) is added dropwise a solution of 2 g (13.9 mmol) of Compound 17 in THF (10 mL) under nitrogen atmosphere. Upon complete addition, the reaction is stirred at room temperature for 18 h. The reaction is cooled in an ice-bath and quenched with addition of 1M aqueous NH4Cl solution (2 mL). The resulting precipitate is removed by filtration through Celite and is rinsed with ethyl acetate (3¡Á100 mL). The filtrate is dried over Na2SO4, filtered and concentrated under reduced pressure to afford 1.63 g of Compound 18 as a colorless oil. Yield: 90%; ES-MS m/z 131 [M+H]; 1H-NMR (500 MHz, CHLOROFORM-d) delta ppm 1.29 (2H, qd, J=12.08, 4.04 Hz), 1.50 (2H, qd, J=6.71, 1.37 Hz), 1.55-1.73 (3H, m), 1.95-2.07 (1H, m), 3.37 (2H, t, J=11.83 Hz), 3.66 (2H, t, J=6.03 Hz), 3.92 (2H, dd, J=11.44, 4.12 Hz)., 85064-61-5

85064-61-5 Tetrahydropyranyl-4-acetic acid 2773575, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; US2011/71196; (2011); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.65412-03-5,4-(2-Aminoethyl)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

A mixture of 2- (5-amino-2- (furan-2-yl) -7H-pyrazolo [4, 3-e] [1, 2, 4] triazolo [1, 5-c] pyrimidin-7-yl) -2-phenylpropanoic acid (100 mg, 0.2570 mmol) , 2- (tetrahydro-2H-pyran-4- yl) ethan-1-amine (40 mg, 0.3085 mmol) , HATU (146 mg, 0.3856 mmol) , DIPEA (99 mg, 0.7712 mmol) in DMF (3 mL) was stirred at rt for 3 hours. The reaction mixture was poured into H 2O (10 mL) and extracted with EtOAc (15 mL x 3) . The combined organic layers were washed with brine, dried over Na 2SO 4, concentrated and purified by column chromatography (DCM/MeOH=40: 110: 1) to give the product (62 mg, 48.2%) . 1HNMR (400 MHz, DMSO-d6) delta 8.24 (s, 1H) , 8.00 (s, 2H) , 7.95 (d, J = 0.9 Hz, 1H) , 7.53 (t, J = 5.6 Hz, 1H) , 7.34 -7.20 (m, 4H) , 7.15 (dd, J = 8.0, 1.4 Hz, 2H) , 6.74 (dd, J = 3.4, 1.8 Hz, 1H) , 3.76 -3.66 (m, 2H) , 3.15 (q, J = 6.6 Hz, 2H) , 3.04 (dd, J = 23.4, 11.6 Hz, 2H) , 2.28 (s, 3H) , 1.51 -1.39 (m, 2H) , 1.37 -1.27 (m, 2H) , 1.26 -1.17 (m, 1H) , 1.02 (ddd, J = 23.9, 12.0, 4.2 Hz, 2H) . MS: M/e 501 (M+1) +., 65412-03-5

As the paragraph descriping shows that 65412-03-5 is playing an increasingly important role.

Reference£º
Patent; BEIGENE, LTD.; ZHANG, Guoliang; ZHOU, Changyou; (152 pag.)WO2019/196803; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29943-42-8,Dihydro-2H-pyran-4(3H)-one,as a common compound, the synthetic route is as follows.

A solution of tetrahydro-4H-pyran-4-one (25 g, 250 mmol) and toluenesulfonylmethyl cyanide (53.7 g, 275 mmol) dissolved in ethylene glycol dimethylether (1 L) was cooled to 0 C. Added dropwise over 30 min was a solution of potassium t-butoxide (56 g, 500 mmol) dissolved in t-butanol (350 mL) and ethylene glycol dimethylether (150 mL). After stirring the resulting mixture for 3 h at room temp, diethyl ether (1 L) was added and the organic phase was washed with saturated aqueous NaHCO3. The organic phase was dried (Na2SO4) and concentrated. The residue was distilled at 39 C. 1.7 mm Hg to give the title compound as colorless oil (10.87 g, 39% yield). 1H NMR (300 MHz, CDCl3) delta: 3.91-3.83 (2H, m), 3.61-3.54 (2H, m), 2.89-2.80 (1H, m), 1.97-1.78 (4H, m).

29943-42-8, The synthetic route of 29943-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Bristol-Myers Squibb Company; US2008/306051; (2008); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110238-91-0,Methyl tetrahydro-2H-pyran-4-carboxylate,as a common compound, the synthetic route is as follows.

Into a 100 mL round-bottom flask, were placed a solution of compound 19.1 (200 mg, 1.39 mmol, 1.00 equiv) in THF (50 mL) and LiA1H4 (63 mg, 1.66 mmol, 1.20 equiv). Reaction was stirred for 3 h at room temperature and then quenched using NaSO4.10H20. The solids were filtered out. Resulting solution was concentrated under vacuum furnish 150 mg (crude) of oxan-4-ylmethanol as a yellow solid.

110238-91-0, 110238-91-0 Methyl tetrahydro-2H-pyran-4-carboxylate 2773520, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; NIMBUS IRIS, INC.; ROMERO, Donna L.; MASSE, Craig E.; ROBINSON, Shaughnessy; GREENWOOD, Jeremy Robert; HARRIMAN, Geraldine; WO2015/48281; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.85064-61-5,Tetrahydropyranyl-4-acetic acid,as a common compound, the synthetic route is as follows.

A solution of methyl 2-amino-5-iodobenzoate (7.02 g, 25.3 mmol) and 2-(tetrahydro-2H-pyran-4-yl)acetic acid (3.76 g, 26.1 mmol) in pyridine (25 mL) was stirred at ?-40¡ã C. under argon while POCl3 (2.58 g, 27.8 mmol) was added dropwise over 3 minutes. The cold bath was immediately removed and the reaction was allowed to stir for 1 hour. The reaction was then diluted with water (75 mL) and extracted with DCM (75 mL). The combined orange organic layers were washed with 6 M aqueous HCl (50 mL), 1 M aqueous HCl (50 mL), and 2 M aqueous K3PO4 (50 mL), dried (Na2SO4), filtered, and concentrated to provide the title compound as an orange solid., 85064-61-5

As the paragraph descriping shows that 85064-61-5 is playing an increasingly important role.

Reference£º
Patent; JOHNSON & JOHNSON; LEONARD, KRISTI A.; BARBAY, KENT; EDWARDS, JAMES P.; KREUTTER, KEVIN D.; KUMMER, DAVID A.; MAHAROOF, UMAR; NISHIMURA, RACHEL; URBANSKI, MAUD; VENKATESAN, HARIHARAN; WANG, AIHUA; WOLIN, RONALD L.; WOODS, CRAIG R.; FOURIE, ANNE; XUE, XIAOHUA; CUMMINGS, MAXWELL D.; MCCLURE, KELLY; TANIS, VIRGINIA; US2015/111870; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

125995-03-1, Atorvastatin lactone is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Form A atorvastatin magnesiumA 6.0 g sample of the lactone form of atorvastatin (United States Patent No. 5,273,995) was dissolved in 100 mL of methanol at room temperature. Approximately 11.8 mL of 1 N NaOH (1.05 mol equivalents) was then added to the mixture. The solution was then stirred at 50 0C for approximately 1 hour. A solution of 1.19g MgCI2-SH2O in 5 mL of H2O (0.55 mol equivalents) was then slowly added to the reaction mixture. The mixture was then cooled to room temperature and the resulting precipitate was removed by vacuum filtration through a 0.45-um nylon membrane filter. Approximately 100 mL of H2O was then slowly added to the filtered solution, which caused a white precipitate to form. The resulting suspension was then stirred for approximately 30 minutes. The solid sample was then isolated by vacuum filtration. The filtered solid was then dried under vacuum at 700C for approximately 2 hours to afford 5.8 g of Form A atorvastatin magnesium. Form B atorvastatin magnesiumA 50 mg sample of Form A atorvastatin magnesium (prepared as described above) was slurried in 0.25 mL of ortho-xylene at 45 oC for 28 days using magnetic stirring at 400 rpm. The solid sample was then isolated by centrifuge filtration through a 0.45-mum nylon membrane filter. The filtered solid was then air dried under ambient conditions for approximately 5 hours to afford Form B atorvastatin magnesium., 125995-03-1

125995-03-1 Atorvastatin lactone 6483036, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; PFIZER PRODUCTS INC.; WO2007/57755; (2007); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.61363-56-2,2H-Pyran-3,5(4H,6H)-dione,as a common compound, the synthetic route is as follows.

61363-56-2, EXAMPLE 34 5-(2,1,3-benzoxadiazol-5-yl)-5,10-dihydro-1H,3H-dipyrano[3,4-b:4, 3-e]pyridine-4,6(7H,9H)-dione A mixture of tetrahydropyran-3,5-dione (Terasawa, J. Org. Chem. (1977), 42, 1163-1169) (0.27 g, 2.4 mmol), 2,1,3-benzoxadiazole-5-carboxaldehyde (Gasco, A. M. Eur.J.Med.Chem.Chim.Ther. (1996), 31,3-10) (0.54 g, 2.9 mmol) and the product from Example 11C (0.27 g, 2.4 mmol) in ethanol (3 mL) was processed as described in Example 29 to provide the title compound (0.088) as a solid. mp>260 C.; MS (ESI(-)) m/z 338 (M-H)31; H NMR (DMSO-d6) delta 4.08 (s, 4H), 4.54 (AB q, 4H), 5.06 (s, 1H), 7.61 (m, 2H), 7.97 (d, 1H), 10.23 (bs, 1H); Anal. Calcd for C17H13N3O50.5 C2H6O: C, 59.15; H, 4.26; N,11.83. Found: C, 59.09;H, 4.32; N, 11.99.

As the paragraph descriping shows that 61363-56-2 is playing an increasingly important role.

Reference£º
Patent; Abbott Laboratories; US6642222; (2003); B2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.

Into a 250-mL round-bottom flask, was placed 4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-2-[(l2R)- l2-methyl-l3-oxa-2,4,l0-triazatricyclo[7.4.0.0A[3,7]]trideca-l(9),2,5,7-tetraen-l0-yl]benzoic acid (1.6 g, 1 equiv), DCM (20 mL), 3-nitro-4-[[(oxan-4-yl)methyl]amino]benzene-l- sulfonamide (890 mg, 1.2 equiv), DMAP (1.25 g, 4 equiv), EDCI (980 mg, 2 equiv). The resulting solution was stirred for 14 hr at room temperature. The resulting mixture was concentrated. The residue was applied onto a silica gel column with EA/DCM (1/10). This resulted in 0.82 g of 4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl]piperazin-l-yl)-2-[(l2R)-l2-methyl-l3-oxa-2,4,l0- triazatricyclo[7.4.0.0A[3,7]]trideca-l(9),2,5,7-tetraen-l0-yl]-N-(3-nitro-4-[[(oxan-4- yl)methyl]amino]benzenesulfonyl)benzamide as a yellow solid. LC-MS (ES, m/z): 923 [M+l]+; RT = 3.50 min. 1H NMR (300 MHz, CDCl3, ppm): d 12.48 (s, 1H), 8.62 (d, / = 2.4 Hz, 2H), 8.54-8.38 (m, 1H), 8.16-7.95 (m, 1H), 7.81-7.71 (m, 1H), 7.32-7.12 (m, 6H), 7.07 (t, J = 2.9 Hz, 1H), 6.97-6.77 (m, 3H), 6.76-6.60 (m, 2H), 6.52 (s, 1H), 6.09 (d, J = 3.0 Hz, 1H), 4.88 (d, J = 7.7 Hz, 1H), 4.02 (dd, J = 11.8, 4.2 Hz, 2H), 3.55-3.34 (m, 4H), 3.32-3.14 (m, 5H), 3.08 (s, 1H), 2.77 (d, J = 9.6 Hz, 2H), 2.28 (s, 3H), 2.19 (s, 2H), 1.99 (d, / = 7.6 Hz, 4H), 1.72 (d, / = 12.7 Hz, 2H), 1.45 (ddd, / = 24.5, 12.3, 5.8 Hz, 6H), 0.94 (d, / = 2.1 Hz, 6H)., 1228779-96-1

1228779-96-1 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 57474953, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; NEWAVE PHARMACEUTICAL INC.; CHEN, Yi; (475 pag.)WO2020/41406; (2020); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.

General procedure: To a solution of appropriate crude acid (1 eq) in CH2Cl2 wereadded EDCI (3 eq), DMAP (0.3 eq) and DIPEA (3 eq). The solutionwas stirred at room temperature for 0.5 h and compound 23 [7] (0.8eq) was added. The resulting mixture was stirred for another 8 hand water was added. The layers were separated, and the aqueouslayer was extracted with CH2Cl2. The combined organic layer waswashed with brine, dried over anhydrous Na2SO4, filtered, andconcentrated under vacuo. The residue was prified by chromatography(CH2Cl2/CH3OH 40:1) to provide target compounds 27a-i,28a-d and 34a-c.

1228779-96-1, The synthetic route of 1228779-96-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Liu, Xiaohua; Zhang, Yu; Huang, Wenjing; Luo, Jia; Li, Yang; Tan, Wenfu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 159; (2018); p. 149 – 165;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

141095-78-5, 2-Bromo-1-(tetrahydro-2H-pyran-4-yl)ethanone is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a mixture of 2-mercapto-4,6-dimethylnicotinonitrile (50 mg, 0.30 mmol, 1 equivalent) in isopropyl alcohol (2 mL) was added 2-bromo-l-(tetrahydro-2H-pyran-4-yl)ethan- 1-one (0.045 mL, 0.37 mmol, 1.2 equivalent) and 10% potassium hydroxide (0.28 mL). After 10 minutes, the reaction was concentrated in vacuo. Purification by reverse phase HPLC afforded 32 mg (37%) of the title compound. 1H NMR (400 MHz, OMSO-d6) delta 7.76 (s, 2H), 7.08 (s, 1H), 3.92 (d, J= 11.1 Hz, 2H), 3.45 (ddd, J= 11.0, 11.2, 3.0 Hz, 2H), 2.97-2.91 (m, 1H), 2.72 (s, 3H), 2.52 (s, 3H), 1.72-1.66 (m, 4H); ES-MS [M+l]+: 291.2., 141095-78-5

The synthetic route of 141095-78-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VANDERBILT UNIVERSITY; LINDSLEY, Craig W.; ENGERS, Darren W.; CONN, P. Jeffrey; BOLLINGER, Katrina A.; CAPSTICK, Rory; SPEARING, Paul; BOLLINGER, Sean R.; (72 pag.)WO2018/85808; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics